Critical Survey: Nuvation Bio (NYSE:NUVB) vs. Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Nuvation Bio (NYSE:NUVB – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Lucid Diagnostics and Nuvation Bio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics 1 0 4 0 2.60
Nuvation Bio 1 2 9 0 2.67

Lucid Diagnostics presently has a consensus target price of $4.19, indicating a potential upside of 923.84%. Nuvation Bio has a consensus target price of $12.89, indicating a potential upside of 228.38%. Given Lucid Diagnostics’ higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Nuvation Bio.

Earnings & Valuation

This table compares Lucid Diagnostics and Nuvation Bio”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lucid Diagnostics $5.44 million 15.29 -$58.01 million ($0.40) -1.02
Nuvation Bio $201.73 million 6.87 -$204.63 million ($0.40) -9.81

Lucid Diagnostics has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Lucid Diagnostics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.

Insider & Institutional Ownership

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Lucid Diagnostics and Nuvation Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lucid Diagnostics -892.75% N/A -142.71%
Nuvation Bio -67.38% -45.69% -18.54%

Summary

Nuvation Bio beats Lucid Diagnostics on 7 of the 13 factors compared between the two stocks.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics is a U.S.-based medical diagnostics company focused on identifying esophageal precancer and cancer. Its primary offering is EsoGuard, a DNA-based test designed to detect cellular changes associated with Barrett’s esophagus, a condition that can increase the risk of esophageal cancer. The test is designed to work with EsoCheck, a swallowable balloon device that collects cells from the esophagus for analysis. Together, the products are intended to provide a less invasive approach to evaluating patients for esophageal disease than traditional endoscopic procedures.

About Nuvation Bio

(Get Free Report)

Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.